Awakn Life Sciences

Awakn Life Sciences is a biotechnology company specializing in the research, development, and clinical delivery of psychedelic-assisted therapies for addiction disorders. The company focuses primarily on ketamine and MDMA-based treatment protocols, targeting conditions such as alcohol use disorder that have historically proven resistant to conventional therapeutic approaches. Awakn operates its own network of therapy clinics in the United Kingdom, allowing it to maintain direct oversight of both the clinical and commercial aspects of its treatment programs. This vertically integrated model positions Awakn as one of the few companies in the psychedelics space capable of conducting research and delivering patient care under the same organizational umbrella.

Awakn has made meaningful clinical progress with its lead program, AWAKN-002, a ketamine-assisted therapy protocol designed specifically for alcohol addiction. The program has completed Phase 2 clinical trials, generating data that supports the potential efficacy of ketamine-assisted psychotherapy as a treatment for alcohol use disorder. The company is publicly listed on the NEO Exchange, providing it with access to capital markets as it continues to advance its pipeline and expand its clinical footprint in the UK. These milestones place Awakn among a small cohort of psychedelic medicine companies with actual clinical-stage evidence backing their core therapeutic claims.

Awakn Life Sciences represents an important development within the broader neurotechnology and mental health innovation landscape, where the urgent need for novel addiction treatments is driving significant scientific and commercial interest. The global burden of alcohol use disorder alone affects hundreds of millions of people, and existing pharmacological and behavioral interventions leave a substantial proportion of patients without lasting relief. By combining rigorous clinical research with direct patient delivery through its own clinics, Awakn is helping to establish the infrastructure and evidence base that the psychedelic medicine field will need to achieve mainstream adoption. Its progress in ketamine-assisted therapy offers a meaningful proof of concept for how neurotechnology companies can translate emerging psychedelic science into scalable, regulated clinical practice.